On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval as a new drug for...
Monoclonal antibodies (mAbs) lecanemab and donanemab have been approved for the treatment of early Alzheimer’s disease in the UK and USA respectively while lecanemab...
The eighth version (seventh update) of a living guideline is released. It replaces earlier versions. The latest update includes a strong recommendation for the...
Sotrovimab, a monoclonal antibody already approved for mild to moderate COVID-19 in several countries gets approval by MHRA in the UK. This antibody was intelligently designed...
University College London Hospitals (UCLH) has announced neutralising antibody trial against COVID-19. The announcement on 25 December 2020 says ‘’UCLH doses first patient in...
Existing biologics such as Canakinumab (monoclonal antibody), Anakinra (monoclonal antibody) and Rilonacept (fusion protein) can be exploited as therapeutics that restrain inflammation in COVID-19...